open access

Vol 10, No 2 (2014)
Review paper
Published online: 2014-05-14
Get Citation

Management and treatment costs of non-squamous metastatic or locally advanced non-small cell lung cancer

Cezary Pruszko, Michał Jachimowicz, Agnieszka Kalinowska
Onkol. Prak. Klin 2014;10(2):63-68.

open access

Vol 10, No 2 (2014)
REVIEW ARTICLES
Published online: 2014-05-14

Abstract

This article presents the results of clinical trials of oral vinorelbin (NVBo) in patients with non-small cell lung cancer (NSCLC). We described the results of NAVoTRIAL01, randomized phase II trial, in which 153 patients were randomized to either arm A (treated with oral vinorelbineith cisplatin — NVBo + P, 102 pts.) or arm B (pemetrexed with cisplatin — Pem + P, 51 pts.). Disease control rate was 75% and 76,5% in arms A and B, respectively. Median of progression-free survival was 4.2 and 4.3 months and overall survival 10.2 and 10.8 months in arms A and B, respectively. There were no differences regarding toxicity profile between the study arms.

Based on NAVoTRIAL01 cost analysis of oral vinorelbine and pemetrexed in the treatment of NSCLC was made. In cost calculation, perspective of public payer and patient was taken, but it should be noticed, that the costs are paid mainly by public payer. All crucial direct medical costs of therapy were included. According to the calculations, total cost of treatment Pem + P is about 51.400 PLN and NVBo + P is about 19.300 PLN. It seems that the major component of the therapy costs is the drugs cost (about 80% of total cost).

It may be presumed that the NVBo + P treatment results in much lower cost for public payer and patient than Pem + P. Apart from that, considering clinical efficacy, it appears that the use of NVBo + P in clinical practice is justified.

Abstract

This article presents the results of clinical trials of oral vinorelbin (NVBo) in patients with non-small cell lung cancer (NSCLC). We described the results of NAVoTRIAL01, randomized phase II trial, in which 153 patients were randomized to either arm A (treated with oral vinorelbineith cisplatin — NVBo + P, 102 pts.) or arm B (pemetrexed with cisplatin — Pem + P, 51 pts.). Disease control rate was 75% and 76,5% in arms A and B, respectively. Median of progression-free survival was 4.2 and 4.3 months and overall survival 10.2 and 10.8 months in arms A and B, respectively. There were no differences regarding toxicity profile between the study arms.

Based on NAVoTRIAL01 cost analysis of oral vinorelbine and pemetrexed in the treatment of NSCLC was made. In cost calculation, perspective of public payer and patient was taken, but it should be noticed, that the costs are paid mainly by public payer. All crucial direct medical costs of therapy were included. According to the calculations, total cost of treatment Pem + P is about 51.400 PLN and NVBo + P is about 19.300 PLN. It seems that the major component of the therapy costs is the drugs cost (about 80% of total cost).

It may be presumed that the NVBo + P treatment results in much lower cost for public payer and patient than Pem + P. Apart from that, considering clinical efficacy, it appears that the use of NVBo + P in clinical practice is justified.

Get Citation

Keywords

non-small cell lung cancer, oral vinorelbin

About this article
Title

Management and treatment costs of non-squamous metastatic or locally advanced non-small cell lung cancer

Journal

Oncology in Clinical Practice

Issue

Vol 10, No 2 (2014)

Article type

Review paper

Pages

63-68

Published online

2014-05-14

Bibliographic record

Onkol. Prak. Klin 2014;10(2):63-68.

Keywords

non-small cell lung cancer
oral vinorelbin

Authors

Cezary Pruszko
Michał Jachimowicz
Agnieszka Kalinowska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl